The article, authored by LRF’s scientific leadership, offer unique insights into disease biology and the discussion of lymphoma management across pediatric and adult oncologic disciplines focusing on anaplastic large cell lymphoma. More >

Download the latest edition of Research Report by the Lymphoma Research Foundation. More >

The FDA approves the use of brentuximab vedotin (Adcetris) treatment of adult patients with primary cutaneous anaplastic large cell lymphoma (pcALCL) and CD30-expressing mycosis fungoides (MF)More >

1
2
3

Learn From Experts

The FocusOnALCL.org website is designed to provide helpful information and resources to patients, caregivers, physicians, and others affected by anaplastic large cell lymphoma.

We invite you to browse the website to learn more about ALCL.

Getting the Facts

Anaplastic large cell lymphoma (ALCL) is a rare type of non-Hodgkin lymphoma (NHL), but the second or third most common subtype of T-cell lymphoma. There are three types of ALCL and altogether they comprise about 3 percent of all NHLs in adults and between 10 percent and 30 percent of all NHLs in children. It can present either systemically or in the skin.

Recent Research

Research into anaplastic large cell lymphoma has led to significant advancements in the understanding of the disease. Research continues on multiple fronts to develop better treatments for patients. We hope you will find the information presented here useful in understanding your disease and discussing it with your healthcare team.

Ask the Doctor

The Lymphoma Research Foundation (LRF) provides a comprehensive series of educational programs for people with lymphoma and their loved ones, including a number of in-person conferences on the local, regional and national levels.

Youtube